Abstract
Objective
To investigate the influence of paroxetine on metoprolol concentrations and its effect in patients treated for acute myocardial infarction (AMI) who are routinely given paroxetine as a co-treatment of depression.
Methods
We recruited 17 depressed AMI patients who received metoprolol as a routine part of their therapy (mean dose 75 ± 39 mg/day). Patients were genotyped for CYP2D6 *3, *4 and gene duplication. Metoprolol and α-hydroxy-metoprolol were analyzed in plasma 0, 2, 6 and 12 h post-dose. Heart rates (HR) at rest were registered after each sampling. Paroxetine 20 mg daily was then administered, and all measurements were repeated on day 8.
Results
All patients were genotypically extensive metabolizers (EMs) (nine with *1/*1 and eight with *1/*3 or *4). Following the administration of paroxetine, mean metoprolol areas under the concentration–time curve (AUC) increased (1064 ± 1213 to 4476 ± 2821 nM × h/mg per kg, P = 0.0001), while metabolite AUCs decreased (1492 ± 872 to 348 ± 279 n M × h/mg per kg, P < 0.0001), with an increase of metabolic ratios (MR) (0.9 ± 1.3 to 26 ± 29; P < 0.0001). Mean HRs were significantly lower after the study week at each time point. Mean area under the HR versus time curve (AUEC) decreased (835 ± 88 to 728 ± 84 beats × h/min; P = 0.0007). Metoprolol AUCs correlated with patients’ AUECs at the baseline (Spearman r = −0.64, P < 0.01), but not on the eighth day of the study. A reduction of metoprolol dose was required in two patients due to excessive bradycardia and severe orthostatic hypotension. No other adverse effects of the drugs were identified.
Conclusion
A pronounced inhibition of metoprolol metabolism by paroxetine was observed in AMI patients, but without serious adverse effects. We suggest, however, that the metoprolol dose is controlled upon initiation and withdrawal of paroxetine.
Similar content being viewed by others
References
Sorensen C, Friis-Hasche E, Haghfelt T, Bech P (2005) Postmyocardial infarction mortality in relation to depression: a systematic critical review. Psychother Psychosom 74(2):69–80
Thombs BD, Bass EB, Ford DE et al (2006) Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 21(1):30–38
Chazov EI, Oganov RG, Pogosova GV et al (2007) Clinico-epidemiological program of the study of depression in cardiological practice in patients with arterial hypertension and ischemic heart disease (COORDINATA). Kardiologiia 47(3):29–37
Jiang W, Davidson JR (2005) Antidepressant therapy in patients with ischemic heart disease. Am Heart J 150(5):871–881
Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340(2–3):249–258
Sauer WH, Berlin JA, Kimmel SE (2003) Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 108(1):32–36
Roose SP, Laghrissi-Thode F, Kennedy JS et al (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279(4):287–291
Pollock BG, Laghrissi-Thode F, Wagner WR (2000) Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 20(2):137–140
Yeragani VK, Pohl R, Balon R, Ramesh C, Glitz D et al (2002) Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biol Psychiatry 52(5):418–429
Glassman AH, O’Connor CM, Califf RM et al (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288(6):701–709
Molden E, Garcia BH, Braathen P, Eggen AE (2005) Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 61(2):119–125
Hemeryck A, Belpaire FM (2002) Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 3(1):13–37
Hjalmarson A, Herlitz J, Holmborg S et al (1983) The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67(6 Pt 2):I26–I32
Chen ZM, Pan HC, Chen YP et al (2005) Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366(9497):1622–1632
Freemantle N, Cleland J, Young P et al (1999) Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 318(7200):1730–1737
Olsson G, Rehnqvist N, Sjo’gren A, Erhardt L, Lundman T (1985) Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 5(6):1428–1437
Everts B, Karlson B, Abdon N-J, Herlitz J, Hedner T et al (1997) Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. Eur J Clin Pharmacol 53(1):23–31
McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF et al (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br J Clin Pharmacol 20(6):555–566
Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5(1):6–13
Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al (2003) Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 59(4):303–312
Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J et al (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12(6):465–472
Ramenskaya GV et al (2002) Pheno- and genotyping the prescription of drugs metabolized by CYP2D6. Bull Exp Biol Med 134(2):159–160
Wuttke H, Rau T, Heide R, Bergmann K, Böhm M et al (2002) Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 72(4):429–437
Fux R, Morike K, Prohmer AM et al (2005) Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study. Clin Pharmacol Ther 78(4):378–387
Zineh I, Beitelshees AL, Gaedigk A, Walker JR et al (2004) Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 76(6):536–544
Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM (2000) Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 67(3):283–291
Kendall MJ, John VA, Quarterman CR, Welling PG (1980) A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol. Eur J Clin Pharmacol 17(2):87–92
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6):361–370
Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62
Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 14(5–6):143–149
Lundqvist E, Johansson I, Ingelman-Sundberg M (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226(2):327–338
Regardh CG, Johnsson G (1980) Clinical pharmacokinetics of metoprolol. Clin Pharmacokinet 5(6):557–569
Koytchev R, Alken RG, Vlahov V, Kirkov V, Kaneva R et al (1998) Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol 54(6):469–474
Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK et al (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19):2363–2372
Toon S, Davidson EM, Garstang FM, Batra H, Bowes RJ, Rowland M (1988) The racemic metoprolol H2-antagonist interaction. Clin Pharmacol Ther 43(3):283–289
The MIAMI Trial Research Group (1985) Metoprolo in acute mycardial infarction. Other clinical findings and tolerability. Am J Cardiol 56(14):39G–46G
Herlitz J et al (2000) Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge. Cardiovasc Drugs Ther 14(6):589-595.
Mautz DS, Nelson WL, Shen DD (1995) Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab Dispos 23(4):513–517
Brynne N, Bottiger Y, Hallen B, Bertilsson L (1999) Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Br J Clin Pharmacol 47(2):145–150
Özdemir V, Naranjo CA, Shulman RW, Herrmann N et al (1998) Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 18(3):198–207
Thurmann PA, Haack S, Werner U, Szymanski J et al (2006) Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent. Clin Pharmacol Ther 80(5):551–553
Acknowledgments
We thank the rector of St. Petersburg I.I.Mechnikov State Medical Academy, professor, and academician of Russian Academy of Medical Sciences Aleksandr V. Shabrov and the coordinator of the Karolinska Institute Research Training Program (KIRT) associate professor Tommy Linne. The help of biomedical analysts Lilleba Bohman in the genotyping techniques and Jolanta Widen in the HPLC techniques is gratefully acknowledged. The research was supported by the Swedish Institute (via KIRT), the Heart-Lung Foundation and the Swedish Research Council (grant No. 3902). The study was approved by the local ethics committees of both institutions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goryachkina, K., Burbello, A., Boldueva, S. et al. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI). Eur J Clin Pharmacol 64, 275–282 (2008). https://doi.org/10.1007/s00228-007-0404-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-007-0404-3